bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, with the potential to dramatically increase overall diagnostic accuracy of lung cancer leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Biotechnology
Industry:
In vitro Diagnostics
NAICS:
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC:
Commercial Physical and Biological Research (8731)
Contact Information
Investor Relations
Julie Anne Overton
Director of Communications
3300 Nacogdoches Road
Suite 216
San Antonio, TX 78217
T: 210-698-5334
jao@bioaffinitytech.com
Company Contact
bioAffinity Technologies, Inc.
3300 Nacogdoches Road
Suite 216
San Antonio, TX 78217
T: 210-698-5334
info@bioaffinitytech.com